Research Analysts Set Expectations for Hims & Hers Health, Inc.’s Q2 2024 Earnings (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) – Research analysts at Leerink Partnrs upped their Q2 2024 earnings per share estimates for Hims & Hers Health in a report released on Tuesday, May 7th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.05 per share for the quarter, up from their previous forecast of $0.02. Leerink Partnrs has a “Market Perform” rating on the stock. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.11 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q3 2024 earnings at $0.05 EPS, FY2024 earnings at $0.18 EPS, FY2025 earnings at $0.29 EPS, FY2026 earnings at $0.45 EPS and FY2027 earnings at $0.67 EPS.

Several other brokerages also recently issued reports on HIMS. Guggenheim raised their price target on Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Jefferies Financial Group reaffirmed a “hold” rating and set a $15.00 price target (down previously from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $14.00 to $16.00 and gave the stock a “hold” rating in a report on Tuesday. SVB Leerink assumed coverage on Hims & Hers Health in a research note on Monday, February 26th. They set a “market perform” rating and a $10.00 target price on the stock. Finally, TheStreet upgraded Hims & Hers Health from a “d” rating to a “c” rating in a research report on Monday, March 4th. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $15.08.

Hims & Hers Health Stock Up 6.3 %

Shares of NYSE HIMS opened at $12.92 on Thursday. The firm’s 50-day moving average price is $13.99 and its two-hundred day moving average price is $10.41. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $17.16. The stock has a market capitalization of $2.77 billion, a P/E ratio of -117.36 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The firm had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. During the same quarter in the previous year, the company posted ($0.05) earnings per share. The firm’s revenue was up 45.8% on a year-over-year basis.

Insider Buying and Selling

In related news, COO Melissa Baird sold 11,750 shares of Hims & Hers Health stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $12.08, for a total value of $141,940.00. Following the transaction, the chief operating officer now directly owns 538,932 shares in the company, valued at approximately $6,510,298.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, COO Melissa Baird sold 11,750 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $12.08, for a total transaction of $141,940.00. Following the sale, the chief operating officer now owns 538,932 shares in the company, valued at $6,510,298.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $12.54, for a total value of $2,368,655.52. The disclosure for this sale can be found here. Insiders have sold 723,602 shares of company stock worth $9,607,432 in the last ninety days. 31.63% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. FNY Investment Advisers LLC bought a new stake in Hims & Hers Health during the 4th quarter valued at approximately $48,000. Avantax Advisory Services Inc. bought a new position in Hims & Hers Health during the first quarter valued at about $156,000. Cornerstone Investment Partners LLC acquired a new position in Hims & Hers Health in the 1st quarter valued at approximately $161,000. EMC Capital Management lifted its position in shares of Hims & Hers Health by 80.0% in the 3rd quarter. EMC Capital Management now owns 12,000 shares of the company’s stock worth $79,000 after acquiring an additional 5,332 shares during the period. Finally, Belpointe Asset Management LLC acquired a new stake in shares of Hims & Hers Health during the 3rd quarter worth approximately $76,000. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.